Members of the National Institutes of Health’s COVID-19 Treatment Guidelines Panel have financial ties to a company behind clinical trials of a drug to treat coronavirus, as well as to another large pharmaceutical company involved with developing a COVID-19 vaccine.
According to the NIH, members of the panel include U.S. physicians, statisticians, and other experts who are developing treatment guidelines on COVID-19 “intended for healthcare providers.”
A total of eight panel members list a financial relationship with Gilead Sciences on the panel’s Financial Disclosure for Companies Related to COVID-19 Treatment or Diagnostics document: Judith Aberg, MD, Adaora Adimora, MD, Jason Baker, MD, Roger Bedimo, MD, Eric Daar, MD, David V. Glidden, PhD, Susanna Naggie, MD, and Pablo Tebas, MD…
To read more visit Just The News.
- Maybe Massive Government Spending And Debt Really Does Cause Inflation? Especially As Trade War Intensifies?
- Russia Says There Is Major Information War Against Their Vaccine…And Frankly They Are Right